HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Chagee Holdings - Thoughts on the IPO Debut and the Valuation Outlook

Shandong Fengxiang (9977.HK) Privatization - Long-Term Investors May Be Unhappy with the Offer Price

Pre-IPO Auntea Jenny (Shanghai) Industrial (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Chagee Holdings - The Business Model, the Concerns Behind and Valuation Outlook

Pre-IPO Chagee Holdings - Some Points Worth the Attention

Mixue Group (2097 HK) - Updates on Valuation Outlook and Growth Forecast Based on 2024 Results

Equity Capital Markets

<ul>
<li>Chagee is seeking up to US$411 million by offering nearly 14.7 million ADS priced between US$26 and US$28 each, with market value to reach about US$4.8-US$5.1 billion.</li>
<li>Chagee is facing performance headwinds. Whether the current high growth of Chagee is sustainable in the future is uncertain. This makes us tend to be conservative in Chagee’s valuation expectations </li>
<li>Based on our forecast, P/E is about 11.5-12.3x if based on 2025 net profit. Such valuation is attractive, but "valuation discount" may occur due to market turmoil and geopolitical conflicts.</li>
</ul>


Chagee is seeking up to US$411 million by offering nearly 14.7 million ADS priced between US$26 and US$28 each, with market value to reach about US$4.8-US$5.1 billion.
Chagee is facing performance headwinds. Whether the current high growth of Chagee is sustainable in the future is uncertain. This makes us tend to be conservative in Chagee’s valuation expectations 
Based on our forecast, P/E is about 11.5-12.3x if based on 2025 net profit. Such valuation is attractive, but "valuation discount" may occur due to market turmoil and geopolitical conflicts.


Pre-IPO Chagee Holdings - IPO Pricing Is Attractive, But Share Price May Underperform